ORIGINAL ARTICLE
Patent Ductus Arteriosus and Development of Bronchopulmonary
–
Dysplasia associated Pulmonary Hypertension
Samuel J. Gentle1, Colm P. Travers1, Matthew Clark2, Waldemar A. Carlo1, and Namasivayam Ambalavanan1
1DivisionofNeonatology,DepartmentofPediatrics,and2DivisionofCardiology,DepartmentofPediatrics,TheUniversityofAlabama
atBirmingham,Birmingham,Alabama
Abstract betweengroups.Aprobitanalysisrelatedthedurationofductal
patencytothedevelopmentofBPD-PH.
Rationale:Extremelypreterminfantswithevolving
MeasurementsandMainResults: Atotalof138infants
bronchopulmonarydysplasia(BPD)areatriskfordevelopment
developedBPDalone,and82infantsdevelopedBPD-PH.After
ofBPD-associatedpulmonaryhypertension(BPD-PH).Apatent
adjustmentfordifferingcovariatesbetweengroups,bothPDA
ductusarteriosus(PDA)shuntmaybeamodifiableriskfactorfor (adjustedoddsratio,4.29;95%confidenceinterval,1.89–9.77)
BPD-PHdevelopment.
andmoderatetolargePDA(adjustedoddsratio,4.15;95%
confidenceinterval,1.78–9.64)remainedsignificantlyrelatedto
Objective:Todeterminewhetherthepresenceanddurationof
BPD-PHatdischarge.Byprobitanalysis,eachadditionalmonth
ductusarteriosuspatencydiffersbetweenextremelypreterm
ofPDAandhemodynamicallysignificantPDAexposurewas
infantswithandwithoutBPD-PH.
associatedwithanincreasedprobabilityforthecomposite
Methods:Weconductedaretrospectivecase-controlstudy outcomeofBPD-PHatdischargeordeathwithcoefficientsof
amongpreterminfantsofgestationalage22weeks,0days,to
0.40(P,0.001)and0.45(P,0.001),respectively.
28weeks,6days,whoremainedonrespiratorysupporton
Conclusions: Inextremelypreterminfantsonrespiratory
postnatalday28attheUniversityofAlabamaatBirmingham
supportonpostnatalday28,boththepresenceofandalonger
from2017to2020.InfantswhowerediagnosedwithPH(cases)
durationofductusarteriosuspatencywereassociatedwiththe
byechocardiographywerecomparedwithinfantswithoutPH
developmentofBPD-PH.
(controlsubjects).Datafromechocardiogramsperformedduring
thehospitalizationafterpostnatalday28wereincluded.Logistic Keywords:bronchopulmonarydysplasia;prematurity; patent
regressionadjustedforcovariatesthatdifferedsignificantly ductus arteriosus;pulmonaryhypertension
Bronchopulmonary dysplasia (BPD) is one pulmonary hypertension (BPD-PH), which risk factors for BPD-PH development is
of the most common morbidities of occurs in (cid:1)17% of infants with BPD (3). needed.
prematurity, occurring in (cid:1)40% of infants Infants who develop BPD-PH are at higher Demographiccharacteristicsreportedto
born at less than 28 weeks’ gestation (1). risk for long-term neurodevelopmental beassociatedwiththedevelopmentofBPD-
Rather than a monomorphic disease, impairment (4) and mortality (3). Given PHincludelowergestationalageandlower
multiple endotypes have been described the severity of adverse outcomes associated birthweight(3).Althoughthepresence(5)
(2), including BPD associated with with BPD-PH, identification of specific andhemodynamicsignificance(6)ofa
(ReceivedinoriginalformMarch22,2022;acceptedinfinalformNovember15,2022)
SupportedbyEuniceKennedyShriverNationalInstituteofChildHealthandHumanDevelopmentgrantR21HD100917-01(S.J.G.)andNHLBI
grantK23HL157618(C.P.T.).
AuthorContributions:S.J.G.helpedwithmanuscriptconceptualization,datacuration,formalanalysis,originaldraftpreparation,review,
andediting.C.P.T.contributedtoformalanalysis,originaldraftpreparation,review,andediting.M.C.contributedtointerpretationofdata
fortheworkaswellasmanuscriptreviewandeditingandprovidedfinalapprovaloftheversiontobepublished.W.A.C.contributedto
conceptualization,interpretationofdataforthework,originaldraftpreparation,andreviewandeditingandprovidedfinalapprovalofthe
versiontobepublished.N.A.contributedtoconceptualization,originaldraftpreparation,reviewandediting,andprovidedfinalapproval
oftheversiontobepublished.
CorrespondenceandrequestsforreprintsshouldbeaddressedtoSamuelJ.Gentle,M.D.,DepartmentofPediatrics,TheUniversityofAlabama
atBirmingham,1700SixthAvenueSouth,Birmingham,AL35233.E-mail:sjgentle@uabmc.edu.
Thisarticlehasarelatededitorial.
Thisarticlehasanonlinesupplement,whichisaccessiblefromthisissue’stableofcontentsatwww.atsjournals.org.
AmJRespirCritCareMedVol207,Iss7,pp921–928,Apr1,2023
Copyright©2023bytheAmericanThoracicSociety
OriginallyPublishedinPressasDOI:10.1164/rccm.202203-0570OConNovember15,2022
Internetaddress:www:atsjournals:org
Gentle, Travers, Clark, et al.: PDA and BPD-associated Pulmonary Hypertension 921
ORIGINAL ARTICLE
day28,iftheyhadatleastone CovariateDefinitions
At a Glance Commentary
echocardiogramperformedafterpostnatal Demographicandbirthcharacteristics
day28,andiftheyremainedonrespiratory comparedbetweencasesandcontrolsubjects
ScientificKnowledgeonthe supportat36weeks’postmenstrualage includedgestationalage,birthweight,small
Subject:Few studies have
(PMA).Infantswhodiedbeforepostnatal forgestationalage,race,sex,preterm
systematically detailed the day28,didnothaveanechocardiogram prematureruptureofmembranes(.24h
association between the presence and
performed,orhadmajorcongenital beforedelivery),andhistologic
duration of ductus arteriosus patency
anomalies(includinghemodynamically chorioamnionitisbyplacentalpathology.
and the development of pulmonary significantcardiaclesions)wereexcluded. Smallforgestationalagewasdefinedasbirth
hypertension in preterm infants. Casesweredefinedasinfantswithevidence weightbelowthe10thpercentilefor
ofPHdiagnosedbycardiology-reviewed gestationalage(10).Clinicalexposures
WhatThisStudyAddstothe
echocardiogramsatanytimeduring comparedbetweencasesandcontrolsubjects
Field:In this case-control study, we
hospitalizationafterpostnatalday28, includedrespiratorysupport(atpostnatal
report that the presence of a patent whereasinfantswithechocardiogramsbut day28and36weeks’PMA)and
ductus arteriosus may be one of the withoutevidenceofPHweredefinedas pharmacologicexposures(corticosteroidsfor
strongest risk factors for pulmonary
controlsubjects. BPDandinhalednitricoxide).Morbidities
hypertension development. AttheUniversityofAlabamaat ofcomparisonincludedBPDat36weeks’
Birmingham,allpreterminfantsreceiving PMAusingJensencriteria(11),grades3to4
respiratorysupportonpostnatalday28are intracranialhemorrhage(12),and
patentductusarteriosus(PDA)havebeen assessedforPHbyechocardiogram,after necrotizingenterocolitisstage>2using
associatedwiththedevelopmentofBPD, whichmonthlyechocardiographic modifiedBell’scriteria(13,14).
thereislimitedevidenceforwhetherthe assessmentisperformeduntildischarge. ForcharacterizationofPDAsthat
presenceandpersistenceofaPDAmaybe Infantsarenotsystematicallyscreenedfora persistedbeyond28days,all
uniquelyassociatedwiththeBPD-PH PDAbeforethispostnataltimepoint,with echocardiogramsperformedonorafter
phenotype(4,7).Moreover,fewofthese (cid:1)35%ofinfantsbeingpharmacologically postnatalday28wereincludedforthe
studiesanalyzedthedurationofductal treateduponPDAdiagnosisduringthestudy analysis.Echocardiographicdiagnoses
patencyandriskforBPD-PH(8).Because period.InfantsbothwithandwithoutBPD- (e.g.,PDA)derivedfromechocardiograms
ductalpatencyvariesovertime,withupto PHmayreceiveatrialofinhalednitricoxide performedbeforepostnatalday28werenot
85%ofPDAsclosingbyhospitaldischarge iftheydeveloprefractoryhypoxemiawhile included.APDAwasfurthercharacterized
inverylowbirthweightinfants(9), receiving100%FIO throughinvasive asmoderatetolargeiftheductaldiameter
characterizationofthedurationofductal ventilation. 2 was>1.5mmwithanyofthefollowing:
patencymayfurtherdefinethepotential
associationbetweenaPDAandBPD-PH.
Weconductedaretrospective,case-
controlstudyininfantswith(cases)and
without(controlsubjects)BPD-PHborn
between220/7weeks’and286/7weeks’
gestationonrespiratorysupportonpostnatal
day28.Wehypothesizedthatamonginfants
withevolvingBPD,thepresenceand
durationofductusarteriosuspatencywould
beassociatedwiththedevelopmentofBPD-
PHafteradjustingfordifferencesinbaseline
characteristics.
Methods
StudyDesign Figure1. Timingofechocardiographicbronchopulmonarydysplasia–associatedpulmonary
Thiswasaretrospectivecase-controlstudy hypertension(BPD-PH)diagnosisandsubsequentdiseasetrajectoryforincludedpatients.
ofprospectivelycollecteddatainpreterm Infantswerestratifiedintothefollowingdynamicgroups:1)newdiagnosisofBPD-PH
infantsbornattheUniversityofAlabamaat
(postmenstrualage[PMA]atwhichBPD-PHwasfirstdiagnosed),2)resolvedBPD-PH
(previouslypresentonpriorechocardiogramwithoutevidenceatindicatedPMA),3)persistent
Birminghambetween2017and2020.
BPD-PH(notedonapreviousandindicatedPMAechocardiogram),and4)noBPD-PH(with
Institutionalreviewboardapprovalwas
noevidenceatindicatedPMAechocardiogramandeitheranypriorechocardiogramor,in
obtainedbeforetheinvestigation.Infants
infantswithpreviousevidenceofBPD-PH,theechocardiogramissubsequenttoapriorstudy
wereincludedifbornbetween220/7and indicatingBPD-PHresolution).ThemedianpostnatalageatBPD-PHdiagnosisincaseswas
286/7weeks’gestation,iftheywere
38weeks’PMA(interquartilerange,33–41).InfantswithBPDwithandwithoutPHhadasimilar
receivingrespiratorysupportonpostnatal numberofechocardiogramsperformedbetweenPMAsof28and40weeks.
922 American Journal of Respiratory and Critical Care Medicine Volume 207 Number 7 | April 1 2023
ORIGINAL ARTICLE
Table1. DemographicandClinical Characteristicsof IncludedPatients estimatesfortheratesofPDAwithincontrol
subjects(20%)andcases(40%).Usingthese
calculations,weestimatedthat58infants
BPDwithNoPH BPD-PH
(n=138) (n=82) PValue withBPD-PHand115infantswithBPD
wouldbeneededforthisanalysis.
ForcomparisonsofPDAsthatpersisted
Demographiccharacteristics,n(%)
Gestationalage,wk* 2662 2562 <0.001 beyond28daysbetweencasesandcontrol
Birthweight,g* 8066209 6556169 <0.001 subjects,thefollowingthreeclassifications
Multiplegestation 30(22) 15(18) 0.54 wereused:1)PDAasabinaryoutcome,
Malesex 80(58) 38(46) 0.09 2)moderateorlargePDAasabinary
Whiterace 60(44) 25(31) 0.06
Antenatalcorticosteroids 127(92) 75(92) 0.88
outcome,and3)thePMAinweeksatwhich
Cesareansection 97(70) 50(61) 0.16 aPDAwaslastidentified.Tofurtherexamine
Histologicchorioamnionitis 64(46) 42(51) 0.49 therelationshipbetweenthedurationofPDA
Smallforgestationalage 18(13) 17(21) 0.13
exposureandBPD-PHdevelopment,parallel
Prolongedruptureofmembranes 36(27) 16(20) 0.23
analyseswereperformedbyPDAstatus,
Clinicalexposures,n(%)
Inhalednitricoxide 18(13) 34(42) <0.001 PDAhemodynamicsignificance,andstrata
CorticosteroidsforBPD 44(32) 62(76) <0.001 ofPDAexposuredaysfortheoutcomesof
PharmacologictreatmentofPDA 19(14) 20(24) 0.05 BPD-PHat28postnataldays,subsequent
RespiratorysupportatDay28
BPD-PHdevelopment,persistentBPD-PHat
Nasalcannula 28(20) 8(10) 0.04
CPAPorNIPPV 69(50) 26(32) 0.008 discharge,anddeath.
Invasivesupport 41(30) 48(59) <0.001 Aprobitregressionwasconductedto
FIO2atpostnatalday28* 0.4460.23 0.5960.27 <0.001 calculatetheprobabilityforpersistentBPD-
BPDseverityat36wkPMA PHordeathusingmonthsof1)anyor
GradeI 90(65) 38(46) 0.006 2)hemodynamicallysignificantductus
GradeII 34(25) 28(34) 0.13
GradeIII 14(10) 16(20) 0.05 arteriosuspatencyexposureasthedose
Otheroutcomes,n(%) variable.Thisregressionwasperformedto
Patentductusarteriosus 29(21) 36(44) <0.001 identifywhetheranincreaseinthenumber
ModeratetolargePDA 19(14) 32(39) <0.001
WeeksofPDAexposure† 6(5–9) 12(7–23) <0.001 ofmonthsofPDAexposure(thepredictor
Grades3–4intracranialhemorrhage 13(9) 11(13) 0.36 variable)wasassociatedwithahigher
Early-onsetsepsis 3(2) 2(2) 0.90 probabilityofBPD-PHdevelopmentor
Late-onsetsepsis 18(13) 21(26) 0.02 death.However,toassessfornonlinear
Severeretinopathyofprematurity 22(16) 21(26) 0.08 associationsbetweencategoricalrangesof
N De ec ar to htizingenterocolitisstage>2 1 61( (8 4)
)
1 14 9( (1 27 3)
)
<0 0. .0 04
01
PDAexposureandBPD-PH–related
outcomes,additionalanalysesby
Definitionofabbreviations:BPD=bronchopulmonarydysplasia;CPAP=continuouspositive logisticregressionwereemployedasnext
airwaypressure;NIPPV=noninvasivepositivepressureventilation;PDA=patentductus described.
arteriosus;PMA=postmenstrualage.
Additionalbivariateanalyseswere
*Average(SD).
†Median(interquartilerange)ininfantswithechocardiographicPDAthatpersistedbeyond28 conductedcomparingbaselinedemographic
days. andclinicalcharacteristicsbetweencasesand
controlsubjects.Aftertestsofnormality,
continuousdatawereanalyzedusingattest
1)ductalsystolicflowvelocity<2.8m/s, Anadditionalexploratoryanalysiswas orMann-Whitneytest.Achi-squaretestwas
2)reversediastolicflowinthedescending performedininfantswithBPD-PHto usedforcategoricalvariables.TheBox-
aorta,or3)ratioofleftatriumtoaorticroot furtherdefinethelongitudinalrelationship
Tidwellprocedurewasusedtodeterminethe
>1.6.Thetimeofductalclosurewasdefined betweenaPDAandBPD-PHpersistence linearityofcontinuouscovariatesfrom
asthepostnatalageatwhichductalpatency andresolution.InfantswithBPD-PHwere whichtheappropriateregressionmodelwas
waslastidentifiedbyechocardiogram. stratifiedintoinfantswithresolutionofBPD-
selected.Inconsideringthemostappropriate
PH,infantswithpersistenceofBPD-PH,and regressionmodel,separatelogisticregression
OutcomeDefinitions infantswhodied.Infantswerecharacterized modelswereemployedfortheoutcomesof
InfantswerediagnosedwithBPD-PHifany ashavingresolvedorpersistentBPD-PH 1)BPD-PHatdischarge,2)BPD-PHat
ofthefollowingechocardiographicfindings basedonthepresenceorabsenceofPHon dischargeordeath,and3)prespecifiedstrata
(15)werepresent:1)elevatedright thelastechocardiogramperformedduring ofPDAexposureduration(,4wk,4–7wk,
ventricularpressuresasestimatedby thehospitalization. 8–11wk,and>12wk).Modelsincorporated
tricuspidjetvelocitymeasurement(with bothcategoricalandcontinuous
rightventricularsystolicpressureestimate StatisticalAnalysis demographiccharacteristicsthatdiffered
of>35mmHg),2)bidirectionalflow Todetermineanadequatesamplesize,we betweencasesandcontrolsubjects(P,0.10)
throughthepatentforamenovaleorPDA,or usedatwo-sidedconfidenceinterval(CI)of aftercalculationofbivariatecorrelationand
3)interventricularseptumflatteningbased 95%,80%power,anexpectedratioofcontrol varianceinflationfactortestingfor
onend-systoliceccentricityindex.1.0. subjectstocasesof2:1,andpreliminary multicollinearity.
Gentle, Travers, Clark, et al.: PDA and BPD-associated Pulmonary Hypertension 923
Resultsweresummarizedusingodds
ratios,95%CIs,andPvaluesdefining
significanceas,0.05.Analyseswere
conductedusingIBMSPSSStatistics26for
Windows,GraphPadPrism,andMedCalc.
Giventhecollinearitybetween
demographiccharacteristicsandboth
spontaneousductalclosureandPH,
amediationanalysiswasperformedbetween
aPDAandBPD-PHusingbirthweightas
themediatorvariable.Thisassessedwhether
theassociationbetweenPDApersistence
beyond28daysandBPD-PHresultedfrom
indirecteffectsbetweenaPDAandbirth
weightorbirthweightandBPD-PH.
Results
Ofthe398infantsbornduringtheinclusion
period,82infantsmetcasecriteriaforBPD-
PH,138infantsmetcontrolcriteriaforBPD
alone,and178infantsdidnotdevelopBPD.
Atotalof463echocardiogramsfromcases
werereviewed(medianof5echocardiograms
perpatient)and461echocardiogramsfrom
controlsubjectswerereviewed(medianof3
echocardiogramsperpatient).Themedian
postnatalageatBPD-PHdiagnosisincases
was38weeks’PMA(interquartilerange,
33–41),withthedistributionofpostnatalage
atBPD-PHdiagnosis,resolution,and
persistencefurtherdepictedinFigure1.
Themedianintervalsbetweenpatients’
echocardiogramsininfantswithBPDand
BPD-PHwere30and29days,respectively.
Themeangestationalagediffered
betweencases(2562)andcontrolsubjects
(2662;P,0.001),andcaseswereborn
atalowerbirthweight(6556169gvs.
8066209g;P,0.001)(Table1).Regarding
clinicalexposures,casesweremore
frequentlyexposedtoinvasiveventilation
(59%vs.30%)andhadahigherFIO (0.59vs.
2 0.44)onpostnatalday28.Morecaseshada
PDA(44%vs.21%)andamoderatetolarge
PDA(39%vs.14%).ThePDAwasmore
frequentlytreatedwithpharmacotherapyin
casesthanincontrolsubjects(24%vs.14%)
(Table1).
ForanalysesbyPDAstatus,the
presenceofaPDApersistentbeyond28
postnataldayswasassociatedwithahigher
frequencyofsubsequentBPD-PH
development(49%vs.28%;P=0.003),
persistenceofBPD-PHatdischarge(34%vs.
14%;P,0.001),anddeathorBPD-PHat
discharge(39%vs.17%;P,0.001)
comparedwithinfantswithoutaPDA.
sutatS
susoiretrAsutcuDtnetaPyb
,semoctuOnoisnetrepyH
yranomluPhtiwnoitaicossAaisalpsyDyranomlupohcnorB
.2elbaT
erusopxE*ADPfonoitaruD
eulaVP
kw21>
kw11–8
kw7–4
eulaVP
ADPH
ADP
ADPH
ADP
ADPH
ADP
*ADPH
*ADP
*ADPoN
||ADPH
§ADP
)61=n(
)22=n(
)8=n(
)51=n(
)72=n(
)82=n(
‡ADPH
†ADP
)15=n(
)56=n(
)551=n(
100.0<
100.0<
)18(31
)86(51
)31(1
)72(4
)62(7
)81(5
100.0<
100.0
)14(12
)73(42
)71(62
htaedroegrahcsidtaecnetsisrepHP-DPB
100.0<
100.0<
)96(11
)95(31
)31(1
)41(4
)62(7
)41(4
100.0<
100.0
)73(91
)23(12
)41(12
egrahcsidtaecnetsisrepHP-DPB
100.0<
100.0<
)36(01
)64(01
)0(0
)7(1
)11(3
)11(3
100.0<
200.0
)62(31
)22(41
)7(11
htaeD
100.0<
100.0<
)05(8
)63(8
)0(0
)7(1
)11(3
)7(2
100.0<
100.0
)22(11
)71(11
)4(6
egrahcsidtaecnetsisrepHP-DPB
300.0
10.0
)6(1
)5(1
)0(0
)0(0
)0(0
)0(0
70.0
21.0
)2(1
)2(1
)1(1
egrahcsidtanoituloserHP-DPB
48.0
08.0
)6(1
)5(1
)0(0
)0(0
)0(0
)4(1
07.0
48.0
)2(1
)3(2
)3(4
noitazilatipsohgnirudHP-DPBoN
100.0<
100.0<
)49(51
)28(81
)05(4
)35(8
)84(31
)63(01
100.0<
100.0<
)36(23
)55(63
)03(64
noitazilatipsohgnirudHP-DPB
100.0<
100.0<
)81(4
)81(4
)0(0
)0(0
)0(0
)0(0
10.0
40.0
)8(4
)6(4
)1(2
d82tadesongaiD
100.0<
100.0<
)96(11
)46(41
)05(4
)35(8
)84(31
)63(01
100.0<
300.0
)55(82
)94(23
)82(44
d82retfadesongaiD
.susoiretrasutcudtnetap=ADP;susoiretrasutcudtnetapegralotetaredom=ADPH;noisnetrepyhdetaicossa–aisalpsydyranomlupohcnorb=HP-DPB:snoitaiverbbafonoitinifeD
.syadlatantsop82>tademrofrepmargoidracohcenodesabsutatsADP*
.ADPtuohtiwdnahtiwstnafnineewtebnosirapmocerauqs-ihcyB†
.ADPegralotetaredomtuohtiwdnahtiwstnafnineewtebnosirapmocerauqs-ihcyB‡
.erusopxeADPfonoitarudybnosirapmocdnertroftsetraenil-yb-raenilerauqs-ihcyB§
.erusopxeADPtnacifingisyllacimanydomehfonoitarudybnosirapmocdnertroftsetraenil-yb-raenilerauqs-ihcyB||
ORIGINAL ARTICLE
924 American Journal of Respiratory and Critical Care Medicine Volume 207 Number 7 | April 1 2023
ORIGINAL ARTICLE
Table3. OddsRatiosof BronchopulmonaryDysplasia–associated Hypertension–relatedOutcomes,by ClinicalCovariates
BPD-PHatDischarge BPD-PHatDischargeorDeath
95%CI 95%CI
Adjusted Adjusted
Variable OR* Lower Upper PValue OR* Lower Upper PValue
Birthweight† 0.75 0.59 0.95 0.02 0.77 0.61 0.97 0.03
Gestationalage‡ 1.23 0.94 1.62 0.13 1.12 0.86 1.45 0.40
Malesex 1.13 0.53 2.42 0.75 1.79 0.86 3.71 0.12
Whiterace 0.76 0.33 1.75 0.52 0.65 0.30 1.43 0.28
F InIO va2sa it vepo vs etn na tilt aa tl iod nay da2 y8§
28
11 .. 12 69 01 .. 40 57 31 .. 05 15 00 .. 70 607 11 .. 71 18 01 .. 70 10 41 .. 14 10 00 .. 20 35
PDA 4.29 1.89 9.77 <0.001 3.50 1.64 7.49 0.001
ModeratetolargePDA|| 4.15 1.78 9.64 <0.001 3.02 1.38 6.59 0.005
PDAexposureduration¶
4–7wk
PDA 1.50 0.16 14.04 0.72 1.81 0.31 10.58 0.51
HPDA 6.12 1.28 29.27 0.02 3.88 0.79 19.03 0.10
8–11wk
PDA 3.15 1.09 9.11 0.03 2.30 0.82 6.39 0.11
HPDA NS NS NS NS NS NS NS NS
>12wk
PDA 6.95 2.48 19.47 <0.001 6.22 2.31 16.76 <0.001
HPDA 3.78 1.28 11.14 0.02 3.21 1.12 9.21 0.03
Definitionofabbreviations:BPD-PH=bronchopulmonarydysplasia–associatedhypertension;CI=confidenceinterval;HPDA=moderatetolarge
patentductusarteriosus;NS=notsignificant;OR=oddsratio;PDA=patentductusarteriosus.
*Analysisbylogisticregressionadjustingforbirthweight,gestationalage,Whiterace,malesex,invasiverespiratorysupportatpostnatalday
2 †F8 o, rF eIO v2ea rytp 1o 0s 0t -n gat ca hl ad na gy e2 i8 n, ba in rtd hP wD eiA g.
ht.
‡Foreveryweekofgestation.
§ ||AFo dr jue sv tee dry O1 R0% foc rh ma on dg ee rain teF oIO r2.
largePDAbylogisticregressionadjustingforbirthweight,gestationalage,Whiterace,malesex,invasive
¶re Ls op gi ir sa tt io cry res gu rep sp so iort na ft op ro ds utn raa tt ia ol nd oa fy P2 D8 A,a an nd dF HIO P2Da Atp eo xpst on sa uta reld ua sy ing28 a.C foo ue r-ff leic vie en lt cs af to er goc ro icv aa lri va ate ris abar lee :a ,v 4ail wab k,le 4–in 7T wa kb ,le 8–E 11 1.
wk,and>12wk
Cad oj eu fs fit cin ieg nf to sr fob rir cth ovw ae ri ig ath et s,g ae resta at vio an ilaa bl la eg ie n, TW ah bi lt ee sra Ec 2e a, nm da Ele 3.sex,invasiverespiratorysupportatpostnatalday28,andFIO2atpostnatalday28.
Similarly,ahemodynamicallysignificant reflectedpulmonarydiseaseindependentof 0.40(P,0.001)and0.45(P,0.001),
PDAwasassociatedwithpersistenceof PHstatus.Thefollowingcovariatesremained respectively(Figure2).Ascoefficientswere
BPD-PHatdischarge(37%vs.14%; significantlyassociatedwiththeBPD-PHat positive,thistranslatestoeachadditional
P,0.001)anddeathorBPD-PHat discharge:PDA(adjustedoddsratio[aOR], monthofPDAexposureincreasesthe
discharge(41%vs.18%;P,0.001) 4.29;95%CI,1.89–9.77),amoderatetolarge probabilityofBPD-PHatdischargeordeath;
comparedwithinfantswithouta PDA(aOR,4.15;95%CI,1.78–9.64),birth however,thisdoesnotprovideamagnitude
hemodynamicallysignificantPDA.There weight(aOR,0.75;95%CI,0.59–0.95),and ofeffect,giventhenonlinearityofprobit
wasanassociatedincreaseinBPD-PHat FIO atpostnatalday28(aOR,1.29;95%CI, analysis(e.g.,thechangeinpredicted
dischargeanddeathininfantswithBPD-PH
1.072–1.55).Thesamecovariateswere
probabilityofBPD-PHatdischargeordeath
withlongerdurationsofPDAor significantfortheoutcomeofBPD-PHat isnotconstantbetweenmonthsofPDA
hemodynamicallysignificantPDAexposures dischargeordeath.Regressionanalysesby exposure).
(Table2). PDAexposuredurationweremost IncharacterizingthetrajectoryofBPD-
Testsformulticollinearityincovariates significantforexposure>12weeksforboth PHincases,BPD-PHresolvedin39infants
differingbetweencasesandcontrolsubjects PDAandmoderatetolargePDAduration (48%)andpersistedin43infants(52%),of
werenonsignificant,forwhichallvariates (Table3).Covariatecoefficientsfor whom19(23%)infantsdied.Amonginfants
wereretained.Logisticregressionmodels regressionmodelsformoderatetolargePDA withBPD-PH,thosewithamoderatetolarge
adjustedforbirthweight,gestationalage, andstrataofPDAexposuredurationcanbe PDAthatpersistedbeyond28dayswere
Whiterace,malesex,FIO,andinvasive foundinTablesE1–E3intheonline morelikelytodie(12of32;38%)thanthose
2
ventilationonpostnatalday28betweencases supplement. withoutamoderatetolargePDA(7of46;
andcontrolsubjects(Table3).Invasive Byprobitanalysis,thedurationofPDA 15%;P=0.01)(Table2).
ventilationandFIO exposureonpostnatal andhemodynamicallysignificantPDA Forthemediationanalysis,indirect
2
day28wereincludedtodiscriminate exposureincreasedtheprobabilityofBPD- effectswereassessedbetweenaPDAand
whetherthepresenceofapersistentPDA PHatdischargeordeathwithcoefficientsof birthweightandbetweenbirthweightand
Gentle, Travers, Clark, et al.: PDA and BPD-associated Pulmonary Hypertension 925
ORIGINAL ARTICLE
screenforBPD-PH,infantswithBPD-PH
werebornatalowerbirthweight(P,0.001)
andsmallforgestationalage(P,0.01)
comparedwithinfantswithoutBPD-PH
(16).Othercohortstudieshavereportedthat
infantswithBPD-PHaremorefrequently
bornsmallforgestationalage(15)and/orare
bornatalowerbirthweight(8,17,18).In
contrast,fewstudies(19)havereported
femalesexmorecommonlyininfantswith
BPD-PH;mostcohortstudieshavereported
similarratesofBPD-PHbysex(8,16,17).
Previousinvestigatorshavereportedan
associationbetweenaPDAandBPD-PH.
Asystematicreviewandmeta-analysis
identifiedPDAasacharacteristicassociated
withanincreasedriskratioofBPD-PHof
1.2(95%CI,1.0–1.5)ininfantswithBPD(3).
However,therewassignificantvariation
regardingtheassociationbetweenaPDA
andBPD-PHinthosestudiesthatwere
included.Mouraniandcolleagues(8)
prospectivelyscreenedpreterminfants
(n=277)bornbetween500and1,250gfor
thepresenceofPH,ofwhom39infants
(14%)hadBPD-PHat36weeks’PMA.
ComparinginfantswithandwithoutBPD-
PH,aPDAwasidentifiedonpostnatalday7
in47%ofinfantswhodevelopedBPD-PH
andin40%ofinfantswhodidnotdevelop
BPD-PH(P=0.41).APDAatthispostnatal
timepointwasnotassociatedwithBPD-PH
Figure2. Probitanalysisofbronchopulmonarydysplasia–associatedpulmonaryhypertension at36weeks’PMA.Asingle-centerstudyof
(BPD-PH)probabilitybydurationofpatentductusarteriosus(PDA)exposure(A)andmoderate
116preterminfantswithBPDreporteda
tolargePDA(HPDA)exposure(B).LongerdurationsofPDAandHPDAexposurewere
higherprevalenceofsurgicalPDAclosurein
associatedwithahigherprobabilityofBPD-PH.Theprobabilityand95%confidenceinterval
infantswithBPD-PH(48%vs.27%;
areindicatedateachcorrespondingdurationofPDAexposure.
P=0.025)(20).Inthepresentstudy,
comparedwithinfantswithBPDalone,
BPD-PHwithcorrelationcoefficientsof232 withBPDalone(controlsubjects).The preterminfantswhodevelopedBPD-PHhad
and20.004,respectively,whichwerenot associationbetweenbothapersistentPDA ahigherrateofaPDAthatpersistedbeyond
significant(b,0.14;95%CI,20.12to0.44), andapersistentmoderatetolargePDAand 28days(43%vs.22%)andahigherrateofa
becausetheCIwasinclusiveofzero.This BPD-PHremainedsignificantafter persistentmoderatetolargePDA(29%vs.
indicatesthattheassociationbetweenaPDA adjustmentforbaselinecharacteristicsby 11%).Moreover,infantswithlonger
andBPD-PHisnot,inpart,theresultofthe logisticregression.Wealsodeterminedthat durationsofductusarteriosuspatencywere
mediatingvariableofbirthweight. thedurationofPDApersistencewas morelikelytohaveapersistentBPD-PHand
Conversely,thedirecteffectofPDA associatedwithBPD-PH.Infurtheranalyses BPD-PH–associatedmortality.
exposureonBPD-PH,excludingthe stratifyingcasestoinfantswithresolution, Thedurationofductusarteriosus
mediatorvariableofbirthweight,was persistence,ordeathassociatedwithBPD- patencyandriskforBPDalonehasalsobeen
significant(b,1.11;95%CI,0.47–1.76). PH,aPDAwasassociatedwithboth reportedinpreterminfants,whichremains
persistenceofBPD-PHanddeath. relevanttothepresentanalysisbecause
Severalidentifiedbaseline
BPD-PHisacommonendotypeininfants
Discussion characteristicsthatdifferedbetweencases withmoderatetosevereBPD(3).Inastudy
andcontrolsubjectsinthepresentstudy ofinfantsbornat,28weeks’gestationthat
Inthiscase-controlstudyofinfantsborn havebeenreportedpreviously.Compared stratifiedPDAexposureto,7days,7to
between220/7and286/7weeks’gestation withcontrolsubjects,casesweremorelikely 13days,and>14days,infantswitha
withanechocardiogramperformedafter tobebornatalowerbirthweightand moderatetolargePDAfor7to13dayshad
postnatalday28,infantswithBPD-PH gestationalage.Inourpreviouscohortstudy anincreasedoddsratioforBPDordeath
(cases)morefrequentlyhadaPDAthat ofextremelylowbirthweightinfantsin comparedwithinfantswithaPDAfor
persistedbeyond28daysthandidinfants whichanechocardiogramwasperformedto ,7days;however,exposurefor>14days
926 American Journal of Respiratory and Critical Care Medicine Volume 207 Number 7 | April 1 2023
ORIGINAL ARTICLE
wasnotassociatedwithworseoutcomes(21). earlyandlatePDAclosure,infantswithlate notbeenshowntoreduceBPDafterearly
Anotherstudyofpreterminfantsbornat closureweremorelikelytodevelopBPD-PH prophylactictreatment(27)orselectiveuse
,29weeks’gestationstratifiedinfants’ (52%vs.0%)withalatermedianprocedural ininfantswithahemodynamically
exposureby,1week,1–2weeks,and.2 ageatclosure(84vs.32d;P,0.001)(26).In significantPDA(28).However,a
weeksandbylogisticregressionreportedan thepresentstudy,infantswithBPD-PHat conservativeapproachtoaPDApersistent
associationbetweenaPDAdurationand dischargeordeathmorefrequentlyhada beyond28postnataldaysmayincrease
deathorBPD(aOR,1.37;95%CI,1.03–1.82) PDAthatpersistedbeyond28daysafter riskforthedevelopmentofBPD-PH
(22).Becauseotherpostnatalexposuresmay adjustingforbaselinedifferences.Moreover, basedonthepresentstudyfindings.
furthercompoundinfants’BPDrisk, theriskofBPD-PHatdischargeordeathwas Inaddition,themonths’durationbetween
additionaldatafromthisinvestigatorygroup higheramonginfantsexposedtoaPDAfor echocardiogramslimitedtheprecision
haveidentifiedprolongedinvasive >12weeks,butnotamongthosewith
towhichdurationofPDAexposure
ventilation.10daysasacriticalcoexposure shorterdurationsofexposure.Probit couldbeassociatedwithBPD-PH
toprolongedPDAexposurethatmay regressionmodelingfurthersubstantiated development.
mediateinfants’riskforBPD(23,24).Inthe theassociationbetweenlongerdurationsof Inthiscase-controlinvestigationof
presentstudy,thedurationofPDAexposure PDAexposureandriskforBPD-PH. extremelypreterminfants,thepresenceofa
wasassociatedwithBPD-PHafter Therefore,longitudinalmonitoringofductal PDAbeyond28postnataldayswas
adjustmentforbaselinecharacteristics, patencymayprovideanadditionaland associatedwithBPD-PHbutalsowiththe
suggestingthatprolongedPDAexposure potentiallyearliermarkerforBPD-PH persistenceofBPD-PHanddeathininfants
maybespecificallyassociatedwiththe persistenceanddeath. withBPD-PH.Longitudinalmonitoringofa
BPD-PHphenotype. Theprimarylimitationofthisstudyis PDAmayprovideanadditional
Inarecentinvestigationof28infants thatconclusionsarelimitedto echocardiographicmarkerforBPD-PH
withBPD-PHcharacterizingsurvivaland associations.Itisunknownwhetherlatent development.Becausetheseinferencesare
resolution,Arjaansandcolleaguesreported patencyofaductusarteriosusininfants limitedtoassociation,furtherstudyofPDA
thatsuprasystemicpulmonaryartery withBPD-PHcontributestodisease closureininfantsat.28postnataldays’age
pressureswereassociatedwithdeath.The severitywherebyductalligationwould wouldbeneededtodeterminewhethera
proportionofinfantswithaPDAdidnot mitigateBPD-PHpersistence,severity,or reductioninPDAexposuremayprevent
differbetweeninfantswhodied(10of11; death.Thepresenceandpersistenceofa bothBPD-PHanddeathininfantswith
91%)andsurvived11of17(73%;P=0.36) PDAmayonlyimplicateunderlyingBPD- establishedBPD-PH.(cid:1)
(25);however,thepostnatalageatdiagnosis PHwithductalpatencymaintainedby
wasnotreported.Inanobservational elevatedrightventricularpressures.The Authordisclosuresareavailablewiththe
investigationoftheclinicalimpactbetween therapeuticutilityofearlyPDAclosurehas textofthisarticleatwww.atsjournals.org.
References 8.MouraniPM,SontagMK,YounoszaiA,MillerJI,KinsellaJP,BakerCD,etal.
Earlypulmonaryvasculardiseaseinpreterminfantsatriskfor
1.StollBJ,HansenNI,BellEF,ShankaranS,LaptookAR,WalshMC,etal.; bronchopulmonarydysplasia.AmJRespirCritCareMed2015;191:87–95.
EuniceKennedyShriverNationalInstituteofChildHealthandHuman 9.SemberovaJ,SircJ,MiletinJ,KuceraJ,BerkaI,SebkovaS,etal.
DevelopmentNeonatalResearchNetwork.Neonataloutcomesof Spontaneousclosureofpatentductusarteriosusininfants<1500g.
extremelypreterminfantsfromtheNICHDNeonatalResearchNetwork. Pediatrics2017;140:e20164258.
Pediatrics2010;126:443–456. 10.OlsenIE,GrovemanSA,LawsonML,ClarkRH,ZemelBS.New
2.ShepherdEG,ClouseBJ,HasenstabKA,SitaramS,MalleskeDT, intrauterinegrowthcurvesbasedonUnitedStatesdata.Pediatrics
NelinLD,etal.Infantpulmonaryfunctiontestingandphenotypes 2010;125:e214–e224.
inseverebronchopulmonarydysplasia.Pediatrics2018;141: 11.JensenEA,DysartK,GantzMG,McDonaldS,BamatNA,KeszlerM,
e20173350. etal.Thediagnosisofbronchopulmonarydysplasiainverypreterm
3.ArjaansS,ZwartEAH,PloegstraMJ,BosAF,KooiEMW,HillegeHL, infants.Anevidence-basedapproach.AmJRespirCritCareMed
etal.Identificationofgapsinthecurrentknowledgeon 2019;200:751–759.
pulmonaryhypertensioninextremelypreterminfants:asystematic 12.PapileLA,BursteinJ,BursteinR,KofflerH.Incidenceandevolutionof
reviewandmeta-analysis.PaediatrPerinatEpidemiol2018; subependymalandintraventricularhemorrhage:astudyofinfantswith
32:258–267. birthweightslessthan1,500gm.JPediatr1978;92:529–534.
4.NakanishiH,UchiyamaA,KusudaS.Impactofpulmonaryhypertension 13.BellMJ,TernbergJL,FeiginRD,KeatingJP,MarshallR,BartonL,etal.
onneurodevelopmentaloutcomeinpreterminfantswith Neonatalnecrotizingenterocolitis.Therapeuticdecisionsbasedupon
bronchopulmonarydysplasia:acohortstudy.JPerinatol2016;36: clinicalstaging.AnnSurg1978;187:1–7.
890–896. 14.WalshMC,KliegmanRM.Necrotizingenterocolitis:treatmentbasedon
5.RojasMA,GonzalezA,BancalariE,ClaureN,PooleC,Silva-NetoG. stagingcriteria.PediatrClinNorthAm1986;33:179–201.
Changingtrendsintheepidemiologyandpathogenesisofneonatal 15.KrishnanU,FeinsteinJA,AdatiaI,AustinED,MullenMP,HopperRK,
chroniclungdisease.JPediatr1995;126:605–610. etal.;PediatricPulmonaryHypertensionNetwork(PPHNet).Evaluation
6.SchenaF,FrancescatoG,CappelleriA,PicciolliI,MayerA,MoscaF, andmanagementofpulmonaryhypertensioninchildrenwith
etal.Associationbetweenhemodynamicallysignificantpatentductus bronchopulmonarydysplasia.JPediatr2017;188:24–34.e1.
arteriosusandbronchopulmonarydysplasia.JPediatr2015;166: 16.BhatR,SalasAA,FosterC,CarloWA,AmbalavananN.Prospective
1488–1492. analysisofpulmonaryhypertensioninextremelylowbirthweight
7.WaruingiW,MhannaMJ.Pulmonaryhypertensioninextremelylowbirth infants.Pediatrics2012;129:e682–e689.
weightinfants:characteristicsandoutcomes.WorldJPediatr2014;10: 17.AswaniR,HaymanL,NicholsG,LucianoAA,AmankwahEK,LeshkoJL,
46–52. etal.Oxygenrequirementasascreeningtoolforthedetectionoflate
Gentle, Travers, Clark, et al.: PDA and BPD-associated Pulmonary Hypertension 927
ORIGINAL ARTICLE
pulmonaryhypertensioninextremelylowbirthweightinfants.Cardiol andtheassociationbetweenpatentductusarteriosusand
Young2016;26:521–527. bronchopulmonarydysplasia:asecondaryanalysisofthePDA-
18.WeismannCG,AsnesJD,Bazzy-AsaadA,TolomeoC,EhrenkranzRA, TOLERATEtrial.JPediatr2021;229:283–288.e2.
BizzarroMJ.Pulmonaryhypertensioninpreterminfants:resultsofa 24.ClymanRI,HillsNK,CambonieG,DebillonT,LigiI,GascoinG,
prospectivescreeningprogram.JPerinatol2017;37:572–577. etal.Patentductusarteriosus,trachealventilation,andthe
19.TrittmannJK,Gastier-FosterJM,ZmudaEJ,FrickJ,RogersLK,Vieland riskofbronchopulmonarydysplasia.PediatrRes2022;91:
VJ,etal.Asinglenucleotidepolymorphisminthedimethylarginine 652–658.
dimethylaminohydrolasegeneisassociatedwithlowerriskof 25.ArjaansS,HaarmanMG,RoofthooftMTR,FriesMWF,KooiEMW,
pulmonaryhypertensioninbronchopulmonarydysplasia.ActaPaediatr BosAF,etal.Fateofpulmonaryhypertensionassociatedwith
2016;105:e170–e175. bronchopulmonarydysplasiabeyond36weekspostmenstrualage.
20.AnHS,BaeEJ,KimGB,KwonBS,BeakJS,KimEK,etal.Pulmonary ArchDisChildFetalNeonatalEd2021;106:45–50.
hypertensioninpreterminfantswithbronchopulmonarydysplasia. 26.PhilipR,WallerBR,ChilakalaS,GrahamB,StecchiN,ApalodimasL,
KoreanCircJ2010;40:131–136. etal.Hemodynamicandclinicalconsequencesofearlyversusdelayed
21.ClymanRI,HillsNK,LiebowitzM,JohngS.Relationshipbetween closureofpatentductusarteriosusinextremelylowbirthweightinfants.
durationofinfantexposuretoamoderate-to-largepatentductus JPerinatol2021;41:100–108.
arteriosusshuntandtheriskofdevelopingbronchopulmonary 27.FowliePW,DavisPG,McGuireW.Prophylacticintravenous
dysplasiaordeathbefore36weeks.AmJPerinatol2020;37:216–223. indomethacinforpreventingmortalityandmorbidityinpreterminfants.
22.MirzaH,GarciaJ,McKinleyG,HubbardL,SensingW,SchneiderJ,etal. CochraneDatabaseSystRev2010;CD000174.
Durationofsignificantpatentductusarteriosusandbronchopulmonary 28.MitraS,ScrivensA,vonKursellAM,DisherT.Earlytreatmentversus
dysplasiainextremelypreterminfants.JPerinatol2019;39:1648–1655. expectantmanagementofhemodynamicallysignificantpatentductus
23.ClymanRI,KaempfJ,LiebowitzM,ErdeveO,BulbulA,H(cid:1)akanssonS, arteriosusforpreterminfants.CochraneDatabaseSystRev2020;12:
etal.;PDA-TOLERATETrialInvestigators.Prolongedtrachealintubation CD013278.
928 American Journal of Respiratory and Critical Care Medicine Volume 207 Number 7 | April 1 2023
